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Abstract Recent studies have demonstrated that a serpin
variant, K1-antitrypsin Portland (AT-PDX), can inhibit the
mammalian convertase furin. Here, we examine the mechanism
by which this inhibition takes place. We find that furin, which
does not belong to the trypsin-like serine protease family, the
usual targets of serpins, forms an SDS-heat denaturation-
resistant complex with AT-PDX both in vitro and in vivo. AT-
PDX inhibited furin with an association rate constant (kass) of
1.5U106 M31 s31 which is similar to kass values reported for
serpins with trypsin-like enzymes. These results illustrate that
AT can be modified to act essentially as a suicide inhibitor of
furin, an enzyme of the subtilase superfamily of serine proteases.
z 1998 Federation of European Biochemical Societies.
Key words: K1-Antitrypsin; Serpin; Protease inhibitor;
Furin; Subtilase; Mechanism-based inhibition
1. Introduction
The serpin (serine protease inhibitor) superfamily includes
more than 60 proteins that can be subdivided into two major
groups, one being inhibitory, the other non-inhibitory. The
inhibitory serpins are single chain polypeptides of around
400 amino acids involved in modulating proteolytic activity
in processes such as in£ammation, coagulation, ¢brinolysis,
cell di¡erentiation, complement activation and in pathologies
such as Alzheimer’s [1^4]. Like many inhibitors of the ‘stand-
ard mechanism’ class, which includes the ovomucoid third
domain, Kazal and Kunitz inhibitor groups, serpins present
a reactive site loop (RSL) which binds to the active-site cleft
of the protease in a substrate-like manner. The structure of
the RSL of standard mechanism inhibitors does not change
between the free and bound forms, and furthermore the same
structure is exhibited by inhibitors from di¡erent families in
the absence of any sequence similarity. The stability of the
complex formed with standard mechanism inhibitors relies
on topological and charge complementarity between the
RSL and the protease active site which favors the formation
of a Michaelis complex-like structure; thus standard mecha-
nism inhibitors behave as transition state analogs. In contrast,
the RSL of serpins is extremely £exible and assumes several
di¡erent conformations, many of which are not immediately
suitable for binding to the active site of the protease [5^8].
Changing the RSL or the reactive site of serpins is one
approach to the development of protein-based inhibitors. Re-
cently this strategy has led to the development of an engi-
neered serpin mutant, K1-antitrypsin Portland (AT-PDX),
which e⁄ciently inhibited furin [9], a member of the mamma-
lian convertases. Among these proteolytic enzymes that are
responsible for the processing of precursor proteins [10], furin
is certainly the best characterized [11]. This trans-Golgi mem-
brane-associated, calcium-dependent endoprotease that
cleaves on the C-terminal side of the recognition sequence
Arg-X-X-Arg [12], is involved in proteolysis of many precur-
sor molecules in the constitutive secretory pathway. The po-
tential role of furin and other convertases in disease states [13]
has prompted investigators to identify and characterize inhib-
itors in order to control production of biologically active pep-
tides.
Considering that furin belongs to the kexin family of the
subtilase superfamily [14], a serine protease family that has
evolved independently of the trypsin family of serine pro-
teases, we reasoned that thoroughly investigating the mecha-
nism of inhibition of a serpin variant in this context was
particularly compelling. Thus, we examined whether AT-
PDX exhibited typical serpin-like properties with respect to
its inhibition of furin. Formation of an indissociable AT-
PDX/furin complex that completely abolished the enzyme’s
activity suggests that the archetype serpin, K1-antitrypsin,
may be easily modi¢ed to inhibit members of the subtilase
family and that such modi¢cations need not a¡ect its regular
behavior.
2. Materials and methods
2.1. Materials
The £uorogenic substrate, boc-Arg-Val-Arg-Arg-4-methylcoumaryl-
7-amide (RVRR-MCA) and the furin inhibitor, decanoyl-Arg-Val-
Lys-Arg chloromethylketone (dec-RVKR-cmk), were purchased
from Bachem Bioscience Inc. Papain, protease-free bovine serum al-
bumin (BSA), and phenylmethylsulfonyl £uoride (PMSF) were ob-
tained from Sigma; aprotinin was from Boehringer-Mannheim; plas-
ma puri¢ed antitrypsin (AT) from Calbiochem. The bacterial
expression vector pQE-31 and Ni2-NTA a⁄nity resin was obtained
from Qiagen. Protein concentration was determined by Lowry assay
using BSA as a standard. The protective antigen (PA) of anthrax was
a generous gift from Drs. S. Leppla and K. Klimpel (NIH, Bethesda,
MD). Monoclonal antibodies (MON-148 and MON-152) were gener-
ously provided by Dr. Wim Van de Ven (University of Leuven). The
cDNAs and vaccinia virus recombinants for AT-PDX and AT-Pitt
were generous gifts from Dr. Gary Thomas (Vollum Institute) and
Hedral Corp. (Portland, OR).
2.2. Construction, expression and puri¢cation of histidine-tagged
AT-PDX in Escherichia coli
ATs were expressed as polyhistidine fusion proteins using the pro-
karyotic expression vector pQE-31 and the Qiaexpressionist system
(Qiagen) according to the manufacturers’ instructions with slight
modi¢cations. BamHI-KpnI cDNAs encoding ATs without their sig-
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nal peptide were inserted into pQE-31 that replaces the signal peptide
with a polyhistidine a⁄nity tag at the N-terminus. The ATs were
expressed in the JM109 E. coli strain. Up to one liter of culture was
grown at 37‡C to an O.D.600 of 0.7^0.9 upon which induction was
carried out using 2 mM isopropyl-L-D-thiogalactopyranoside (IPTG)
and growth continued for a further 5 h at 30‡C. The production and
native puri¢cation of ATs from total cytoplasmic proteins was then
performed. Cells were harvested, resuspended in 30 ml of S bu¡er (50
mM sodium phosphate, pH 8.0, 300 mM NaCl, 1 mM PMSF, 5 Wg/ml
aprotinin and 5 mM L-mercaptoethanol) containing 1 mg/ml of lyso-
zyme and sonicated. Triton X-100 was then added to the cell lysate at
a ¢nal concentration of 0.1%. Cell debris was removed by centrifuga-
tion at 11 000Ug for 20 min and the supernatant was added onto
Ni2-NTA resin previously equilibrated with S bu¡er. After stirring
at 4‡C for 1 h, the resin was washed twice and centrifuged. The resin
was resuspended in 20 ml of W bu¡er (50 mM sodium phosphate, pH
6.0, 300 mM NaCl, 10% glycerol, 1 mM PMSF, 1 Wg/ml aprotinin,
5 mM L-mercaptoethanol), loaded onto a column and proteins were
eluted with E bu¡er (50 mM sodium phosphate, pH 4.5, 50 mM KCl,
5 mM L-mercaptoethanol); the pH of the eluted samples was imme-
diately adjusted to 7.4. The eluate was applied to a Mono Q HR 5/5
fast protein liquid chromatography (FPLC) anion exchange column
and proteins were eluted with a 100^250 mM NaCl gradient in 10 mM
sodium phosphate (pH 6.5). The purity of ATs was assessed by SDS-
PAGE and AT-containing fractions were aliquoted and stored in
0.1% polyethylene glycol at 380‡C after snap-freezing in liquid nitro-
gen.
2.3. Analysis of reaction products by SDS-PAGE
The susceptibility to proteolysis of bacterially expressed htAT-PDX
was con¢rmed by mobility of the protein (or protein fragments) on
SDS-PAGE after incubation with furin or papain. Furin was pro-
duced as a secreted, soluble form (sfurin) and puri¢ed as previously
described [12,15]. The RSL of htAT-PDX was cleaved by incubation
with papain in P bu¡er (50 mM Tris-HCl, 150 mM NaCl, pH 8.0) for
30 min at 37‡C [16]. AT-PDX was also incubated with furin for
increasing times in 100 mM HEPES, 1 mM CaCl2, 1 mM L-mercap-
toethanol at 30‡C. The cleavage reactions were stopped by adding
Laemmli bu¡er and the cleavage products were assessed by SDS-
PAGE. To avoid the complete degradation of the protein by papain,
the reaction conditions that resulted in the initial cleavage event were
optimized by analyzing cleavages with di¡erent papain concentra-
tions.
2.4. Kinetic assays and determination of inhibition parameters
Progress curves were used to estimate the parameters for the inhib-
ition of furin by AT-PDX. All assays were performed at 30‡C in
I bu¡er (100 mM HEPES, pH 7.5, 1 mM CaCl2, 1 mM L-mercaptoe-
thanol, 500 mg/ml BSA) and 60^100 WM RVRR-MCA. Fluorescence
(380 nm excitation, 460 nm emission) was measured on a Hitachi,
model F-2000 spectro£uorometer. Each progress curve experiment
consisted of 6^9 assays, one in the absence of serpin and others
with AT-PDX at concentrations ranging from 3^15 nM; assays
were initiated by the addition of furin at a ¢nal concentration of
86 pM. The data were ¢t to an equation describing reversible slow
tight-binding inhibition as previously described assuming irreversibil-
ity [17], and the apparent association rate constant derived corrected
for the presence of competing substrate by the relationship kass = kapp
(1+S/Km). A cuvette containing only substrate was included as a con-
trol and the background rate of substrate conversion in the absence of
enzyme was subtracted from the data prior to estimating rate con-
stants.
2.5. Analysis of enzyme/inhibitor complex
The nature of the complex between AT-PDX and furin was exam-
ined in vitro and in vivo. For in vitro analysis, AT-PDX (530 nM)
was incubated with furin (350 pM) for 60 min in I bu¡er at 30‡C; the
complex was incubated with Laemmli bu¡er (with or without DTT)
and either boiled for 3 min or kept at room temperature. Proteins
were resolved on 8% SDS-PAGE and transferred to a nitrocellulose
membrane. The membrane was blocked and then incubated with a
monoclonal anti-furin antibody (MON-148) and developed with the
ECL protocol (Amersham). For in vivo analysis, COS-7 cells grown
on 60-mm dishes were co-infected with wild type (WT) and recombi-
nant vaccinia virus expressing AT-PDX or human furin for 1 h at
37‡C as previously described [18]. Four hours post-infection, cells
were starved for 1 h in MEM medium lacking cysteine/methionine
containing 10% dialyzed FBS and were pulse-labeled with 100 WCi
of [35S]Cys/Met labeling mix (Amersham) for 2 h. Cells were lysed
in mRIPA bu¡er and half the cellular extract was immunoprecipitated
with a polyclonal antibody against K1-antitrypsin (Calbiochem), the
other half with an anti-furin monoclonal antibody, MON-152, as
previously described [19]. Proteins were resolved on 8% SDS-PAGE.
3. Results
3.1. Bacterial expression, puri¢cation and inhibitory properties
of histidine tagged AT-PDX
In order to produce adequate quantities for a thorough
characterization of AT-PDX, we expressed histidine tagged
AT-PDX (htAT-PDX) in E. coli using a procedure developed
by Bischo¡ et al. [20] with modi¢cations. The cDNAs encod-
ing AT-PDX or AT-Pitt were sub-cloned into pQE-31 which
enables insertion of 6 histidine residues at the N-terminal of
the gene of interest. It had previously been reported that the
temperature at which the cultures were grown a¡ected the
solubility and activity of expressed AT recombinants [21].
We noticed that htAT-PDX accumulated mainly as an active
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Fig. 1. Expression and puri¢cation of histidine-tagged AT-PDX
from bacteria. Recombinant htAT-PDX was puri¢ed from IPTG-in-
duced bacterial cell extracts using Ni2-NTA a⁄nity resin and
FPLC. Lane 1: molecular weight markers; lane 2: uninduced bacte-
rial cell extract; lane 3: htAT-PDX induction with 2 mM IPTG;
lane 4: elution of htAT-PDX from Ni2 a⁄nity column; lane 5:
FPLC puri¢cation of htAT-PDX following nickel a⁄nity resin step;
lane 6: plasma puri¢ed AT; lane 7: AT deglycosylated with
PNGase F.
Fig. 2. AT-PDX inhibits furin-dependent proteolysis of PA in vitro.
Furin (86 pM) was pre-incubated with 1.4 WM htAT-PDX for 1 min
(lane 2) or 1 h (lane 3), with 1.4 WM htAT-Pitt for 4 h (lane 4) or
without serpin (lane 5) before the addition of substrate (0.80 WM
PA) in 30 Wl ¢nal volume. The assays were stopped after 1 h with
Laemmli bu¡er and boiled. Lane 1: molecular weight markers; lane
6: PA alone.
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soluble form when bacteria were grown at 30‡C, while most of
htAT-PDX accumulated in an inactive form in inclusion
bodies if cells were grown at 37‡C (data not shown). Fig. 1
shows that following induction with IPTG, a major band of
47 kDa was produced (lane 3). Puri¢cation on the nickel
column (lane 4) enriched our preparation and ultimately
FPLC chromatography yielded 90% pure htAT-PDX (lane
5). For comparison, commercially available, glycosylated
wild-type AT has a molecular weight of 52 kDa (lane 6) which
upon deglycosylation with PNGase F yielded a protein of 47
kDa (lane 7). Up to 3 mg of non-glycosylated htAT-PDX was
produced from 1 l of culture media.
To determine whether this preparation conserved its inhib-
itory properties toward furin, we initially compared K0:5 val-
ues. Bacterially expressed htAT-PDX conserved its property
at inhibiting furin’s capacity to process a synthetic substrate in
a manner that was indistinguishable from AT-PDX produced
in eucaryotic cells [9]. Indeed, the K0:5 of 0.013 Wg/ml obtained
with htAT-PDX from bacterial sources is similar to the K0:5 of
0.030 Wg/ml observed with AT-PDX produced in BSC-40 cells
by a recombinant vaccinia virus [9] (data not shown). In ad-
dition, we veri¢ed whether this preparation e⁄ciently impeded
cleavage of protective antigen (PA) a previously characterized
substrate for furin [12,22]. As shown in Fig. 2, when PA (83
kDa, lane 6) is incubated with furin, two cleavage products of
63 kDa and 20 kDa appear after 60 min (lane 5). Proteolysis
was completely inhibited when furin was pre-incubated with
htAT-PDX for 1 min or 1 h (lanes 2, 3, respectively). Incu-
bation of furin with a similar quantity of htAT-Pitt did not
a¡ect furin’s capacity to cleave PA (lane 4). These results
demonstrate that lack of glycosylation due to the bacterial
expression system used and presence of 6 histidine residues
at the N-terminal of AT-PDX did not decrease its inhibitory
properties toward furin. We therefore used this preparation
for further characterization.
3.2. Proteolysis of htAT-PDX by furin does not produce
peptide fragments
Because htAT-PDX has a furin recognition sequence at its
reactive site, we initially veri¢ed whether incubation of htAT-
PDX with furin yielded free proteolytic fragments; this would
have led to the possibility of a competitive based inhibitory
mechanism. If furin cleaved at the P1^P1P bond (Arg358^
Ser359) and released its proteolytic fragments in a substrate-
like manner, the main chain of the serpin should be lowered
by 3^4 kDa. Fig. 3 shows that prolonged incubation (up to 24
h) of furin with htAT-PDX did not diminish its apparent
molecular weight or yield proteolytic fragments (lanes 2, 3).
Furin’s enzymatic activity was maintained for at least 8 h
since addition of PA at that time resulted in proteolysis of
PA (lane 5). However, to ensure that htAT-PDX was suscep-
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Fig. 4. Kinetic analysis of furin inhibition by AT-PDX. A: Progress
curves for the inhibition of furin by htAT-PDX. Assays were per-
formed as described in Section 2 with 100 WM boc-Arg-Val-Arg-
Arg-MCA, 86 pM of furin and increasing concentrations of htAT-
PDX at 0, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10 and 15 nM, respectively.
B: Irreversibility of the enzyme-inhibitor complex. Furin (86 pM)
was preincubated 1 h without inhibitor (a), with 0.85 WM htAT-
PDX (b and E), with 10 WM (F and R) or 50 WM (O and P) dec-
anoyl-Arg-Val-Lys-Arg-chloromethylketone for 1 h, diluted 40-fold
and 100 WM boc-Arg-Val-Arg-Arg-MCA was added to measure re-
maining enzymatic activity. Two independent assays are shown for
each inhibition condition.
Fig. 3. Inhibition of furin by htAT-PDX does not result in release
of serpin-derived fragments. Furin (86 pM) was incubated with
1.4 WM of htAT-PDX for 30 min (lane 2) or 24 h (lane 3). The sus-
ceptibility to release htAT-PDX-derived fragments was assessed by
incubating htAT-PDX with 0.0001 U of papain for 30 min (lane 4).
Furin viability over long incubation times was veri¢ed by pre-incu-
bating the enzyme 8 h before the addition of 0.80 WM of PA for 1 h
(lane 5). The assays were stopped with Laemmli bu¡er, boiled and
resolved on 10% SDS-PAGE. Lane 1: molecular weight markers;
lane 6: PA alone.
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tible to cleavage, we incubated it with papain. It had been
demonstrated that papain, a cysteine proteinase, e⁄ciently
cleaves AT at Phe352^Leu353 to produce a slightly smaller
fragment [16]. As shown in Fig. 3 (lane 4), htAT-PDX is
fragmented by papain, producing a polypeptide of 46 kDa.
Although a smaller molecular weight form was expected, it is
possible that the N-terminal histidine residues a¡ected the
migration in a way that loss of the C-terminal did not signi¢-
cantly a¡ect its apparent molecular weight. The susceptibility
of htAT-PDX to be cleaved by papain resulting in the detec-
tion of a smaller fragment and its resistance to release a frag-
ment upon proteolysis by furin demonstrated that the local
structure of the RSL was probably maintained but that the
behavior of the serpin towards furin was quite di¡erent than
towards papain.
3.3. Inhibition of furin by AT-PDX is irreversible
To further characterize the nature of the inhibition of furin
by htAT-PDX, kinetic parameters were determined by prog-
ress-curve kinetics ; representative data sets are shown in Fig.
4A,B.
As illustrated, increasing levels of AT-PDX enabled steady-
state equilibrium to be attained more readily. By non-linear
regression, we calculated an association rate constant (kass) of
1.6 þ 0.2U106 M31 s31 (n = 7) which is similar to the kass
observed for inhibition of thrombin by protease nexin 1
(1.5U106 M31 s31) or by AT variants where the P1 position
is substituted with Arg (5.2U105 M31 s31) [23]. We also veri-
¢ed if longer incubation times coupled to a dilution of the
incubation reaction would result in a return of furin’s enzy-
matic activity (Fig. 4B). This experiment was performed be-
cause mutations in the RSL of serpins could lead to the for-
mation of a tight but reversible bond between the inhibitor
and the enzyme [34]. We did not observe a return of activity
after 400 min of incubation suggesting the irreversible nature
of the interaction. Inhibition by the irreversible inhibitor pep-
tidyl-chloromethylketone revealed no furin activity over the
course of the incubation.
3.4. The htAT-PDX/furin complex is resistant to denaturation
and heat
An interesting property of inhibitory serpins is their pro-
pensity to form a complex with the target proteinase that is
resistant to heat and SDS treatment [1]. To characterize the
type of interaction between htAT-PDX and furin, we per-
formed Western blot analysis following SDS-PAGE of sam-
ples containing AT-PDX and furin using a monoclonal anti-
body that recognizes the N-terminus of active furin. Fig. 5A
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Fig. 5. AT-PDX forms a heat- and SDS-resistant complex with furin. A: 530 nM of AT-PDX (lanes 1 and 3) or htAT-Pitt (lanes 4 and 5)
were incubated without (lanes 2 and 4) or with 86 pM of furin (lanes 2, 3 and 5) for 1 h. Western blotting was performed with monoclonal
antibody MON-148 for detection of furin immunoreactivity. B: Formation of AT-PDX-furin complex in vivo. COS-7 cells were infected with
recombinant vaccinia virus expressing native furin (m.o.i. = 2, lanes 2, 4, 6 and 8) and/or AT-PDX (m.o.i. = 4, lanes 3, 4 and 7, 8). Multiplicity
of infection was adjusted to 6 with wild-type vaccinia virus in all lanes. Metabolic labeling with [35S] and immunoprecipitation were carried out
with anti-K1-antitrypsin (lanes 1^4) or anti-furin MON-152 (lanes 5^8) as described in Section 2. AT-PDX-furin complex is indicated. Molecu-
lar weight markers are shown on the left.
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shows that the soluble form of furin (sfurin) migrates as a
protein of 83 kDa (lane 2) in accordance with the previously
reported Mr [24]; the antibody did not recognize htAT-PDX
(lane 1). When sfurin was pre-incubated with htAT-PDX,
boiled in Laemmli bu¡er and resolved on SDS-PAGE, furin
immunoreactivity was detected as a band of approximately
140 kDa (lane 3). This would correspond to the apparent
Mr obtained from a complex of htAT-PDX (47 kDa) and
sfurin (83 kDa). We did not observe formation of this com-
plex when sfurin was pre-incubated with the htAT-Pitt variant
(lane 5). Time-course experiments of complex formation re-
vealed that the 140-kDa complex can be detected after only
1 min of incubation (results not shown). Thus, the AT-PDX/
sfurin complex is resistant to denaturing conditions (SDS and
heat), a property shared with the wild-type AT/elastase com-
plex.
To examine whether this complex could be formed in vivo
we expressed AT-PDX and native furin in COS-7 cells using
vaccinia virus recombinants (Fig. 5B). Pulse labeling experi-
ments show that after 2 h AT-PDX is immunoprecipitated as
two broad bands of 52 and 56 kDa (lane 3), suggesting the
glycosylated nature of the protein. Immunoprecipitations us-
ing the furin-speci¢c antibody, MON-152, in cells expressing
native furin revealed a series of bands at 96, 91 and 87 kDa
representing di¡erent zymogen and active forms of furin (lane
6). We then used either the AT or the furin speci¢c antibodies
to immunoprecipitate solubilized proteins from cells express-
ing both AT-PDX and furin. The results show that a propor-
tion of the expressed AT-PDX interacts with furin to produce
the high molecular weight 190-kDa complex (lanes 4 and 8).
The reasons why not more of the complex is detected may be,
in part, due to the fact that only the enzymatically active and
fully glycosylated form of furin could interact with AT-PDX;
other immunodetected bands representing the zymogen or im-
mature forms of the enzyme may not interact with the serpin.
The ine⁄cacy of the antibody to e⁄ciently recognize the ser-
pin/enzyme complex due to a distortion of the protease may
be another reason for the relatively low levels of detected
complex.
4. Discussion
It has been established that serpins operate as ‘mechanism-
based’ or ‘suicide substrate’ inhibitors, and as such are the
only known proteinaceous inhibitors known to do so. In
this mechanism (Scheme 1), after the formation of an initial
Michaelis complex (EI) follows the formation of an intermedi-
ate complex (EIP), after which the reaction partitions between
two alternative and competing pathways; one which leads to a
stable inhibitor-enzyme complex (EI*) and the other to the
release of free, cleaved, inactive inhibitor (I**) and active
enzyme (E). Once the EI* complex is formed, it can slowly
break down either by a combination of pathways k33 and k4
or by an alternative pathway, k5. The nature of mechanism
based inhibition implies that inhibitor is depleted by the cata-
lytic pathway. The assays done in this work were done under
conditions where such depletion was negligible.
More speci¢cally, formation of the complex between a ser-
pin and a serine proteinase requires four distinct processes: (1)
recognition and interaction between the P1 position of the
serpin and the S1 binding site of the enzyme along with sub-
site interactions (in our case the P4 Arg of AT-PDX); (2)
cleavage of the P1^P1P bond and formation of a covalent
acyl^enzyme bond or tetrahedral intermediate; (3) refolding
of the serpin by insertion of strand 4A into beta sheet A; and
(4) very slow deacylation to release the enzyme.
Antitrypsin and its variants have been extensively used as
model serpins to elucidate the mechanism by which serpins
inhibit serine proteases [5,6,25,26]. However, the majority of
enzymes with which these variants interacted belong to the
trypsin family of serine proteases. Human furin belongs to
peptidase family S8, also known as the subtilase family, and
has a very di¡erent architecture than elastase, the physiolog-
ical target of native AT. Presently, unlike enzymes of the
trypsin family, there exists no ‘natural’ inhibitor to this class
of proteinase. The ¢rst reported inhibition of furin was per-
formed using a peptidyl-chloromethyl ketone (decanoyl-Arg-
Glu-Lys-Arg-chloromethylketone) to abolish production of
gp120, the envelope glycoprotein of HIV [27]. This peptide-
based strategy was employed to inhibit furin or convertase-
mediated processing of other precursors [15,28^31]. Con-
versely, it was also observed that protein-based inhibitors,
for example a variant of the Kazal inhibitor ovomucoid third
domain, could a¡ect convertase activity [32]. By focusing on
known serine protease inhibitors and with the knowledge of
furin’s enzymatic speci¢city, the engineered antitrypsin variant
AT-PDX was produced. This protein, in which the reactive
site AIPM of AT was replaced by the furin recognition site
RIPR, exhibited potent inhibitory properties towards furin
[9]. However, the mechanism by which the protein abolished
the activity of convertase remained unknown.
Based on these results, we initially hypothesized that AT-
PDX acted as a competitive inhibitor towards furin and AT’s
original serpin properties were compromised. This is because
interfering with the mobility of the RSL by modifying residues
on the N-terminal side of the P1^P1P bond [33] has been
shown to diminish or abolish the serpin’s ability to irreversi-
bly inhibit its cognate proteinase [34]. Moreover, recent results
have shown that the P6^P2 region of the reactive site of AT is
important for rapid inhibition and formation of stable serpin-
proteinase complexes [35]. Interaction between AT-PDX and
furin resulted in the formation of an irreversible complex re-
sistant to heat and denaturation. Therefore, replacement of
the P1 and P4 residues in AT-PDX did not alter the serpin’s
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Scheme 1.
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capacity to form the high molecular weight complex in vitro
or in vivo. To our knowledge, this is the ¢rst time that an AT
variant demonstrates serpin-like properties towards a serine
protease of the mammalian subtilase family. Recently, reports
have shown that wild-type AT can inhibit and form a complex
with a bacterial enzyme, subtilisin Carlsberg [36], while other
studies have demonstrated how the tobacco hornworm Man-
duca sexta can produce, through alternative exon usage, a
variety of serpins, one of which (serpin 1B) also inhibited
subtilisin Carlsberg [37]. Moreover, it has been observed
that proteins having high sequence similarities to serpins
have the potential to inhibit proteinases belonging to other
classes of endoproteases. For example, the demonstration by
Mathialagan and Hansen [38] that ovine uterine serpin,
OvUS-1, could speci¢cally bind to pepsin, an aspartic protein-
ase, provided evidence of a serpin with ‘crossover’ activity.
The CrmA protein from cowpox virus that attenuates the
enzymatic activity of FLICE, a cysteine proteinase, is another
example of a serpin with ‘cross-class’ interactions [39].
Recent reports have described how AT-PDX has been used
to control production of biologically active peptides by inhib-
iting furin in various expression systems. Heterologous expres-
sion of the serpin suppressed the stretch-induced hypertrophic
growth of cardiocytes as well as the processing of brain-type
natriuretic peptides [40], controlled growth of pancreatic beta
cells [41] and inhibited processing of viral glycoprotein pre-
cursors [42]. Here, we have investigated the mechanism by
which such inhibition takes place. With the continued phar-
macological interest in the development of enzyme inhibitors,
it is to be expected that other serpin variants will be engi-
neered or discovered that selectively recognize other mamma-
lian convertases. However, both in vivo and in vitro assays
will be needed to assess serpin speci¢city and physiological
relevance. It is well described that, depending on the type of
assay used, contrasting results have been obtained when the
inhibitory pro¢les of AT variants were evaluated [43^45], but
progress towards delineating such selectivity is forthcoming.
The pattern of interaction that we have described herein
should be helpful in determining the inhibitory features of
such molecules.
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